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Estragole is a naturally occurring food-borne genotoxic 
compound found in a variety of food sources, includ-
ing spices and herbs. This results in human exposure to 
estragole via the regular diet. The objective of this study 
was to quantify the dose-dependent estragole–DNA 
adduct formation in rat liver and the urinary excretion 
of 1'-hydroxyestragole glucuronide in order to validate 
our recently developed physiologically based biodynamic 
(PBBD) model. Groups of male outbred Sprague Dawley 
rats (n = 10, per group) were administered estragole once 
by oral gavage at dose levels of 0 (vehicle control), 5, 30, 75, 
150, and 300 mg estragole/kg bw and sacrificed after 48 h. 
Liver, kidney and lungs were analysed for DNA adducts by 
LC-MS/MS. Results obtained revealed a dose-dependent 
increase in DNA adduct formation in the liver. In lungs and 
kidneys DNA adducts were detected at lower levels than in 
the liver confirming the occurrence of DNA adducts pref-
erably in the target organ, the liver. The results obtained 
showed that the PBBD model predictions for both uri-
nary excretion of 1'-hydroxyestragole glucuronide and the 
guanosine adduct formation in the liver were comparable 
within less than an order of magnitude to the values actu-
ally observed in vivo. The PBBD model was refined using 
liver zonation to investigate whether its predictive potential 
could be further improved. The results obtained provide the 
first data set available on estragole–DNA adduct formation 
in rats and confirm their occurrence in metabolically active 
tissues, i.e. liver, lung and kidney, while the significantly 
higher levels found in liver are in accordance with the liver 
as the target organ for carcinogenicity. This opens the way 
towards future modelling of dose-dependent estragole liver 
DNA adduct formation in human.
Introduction
The human diet is highly complex and a variety of naturally 
occurring genotoxic carcinogens can be found in food. One 
common mechanism and a presumed prerequisite for the car-
cinogenicity of most genotoxic compounds is the formation 
of DNA adducts (1). Analysis of DNA adducts has been used 
to complement data on carcinogen exposure, metabolism, 
mutation and tumour formation. The difficulties in assess-
ing the risk of naturally occurring genotoxic carcinogens are 
well illustrated by the case of estragole. Estragole is present 
in spices and herbs such as basil, anise, fennel, bay leaves and 
tarragon, and in their essential oils and it is thus present in a 
variety of foods with a long history of human use, traditionally 
considered as safe. However, estragole is known to be hepa-
tocarcinogenic at high doses in rodents (2). Estragole itself is 
not reactive but upon its rapid absorption in the gastrointestinal 
tract it is transported to the liver, where the compound is bioac-
tivated (3). Metabolism of estragole can follow different path-
ways (Figure 1). Estragole is detoxified via O-demethylation 
to 4-allylphenol or epoxidation to estragole 2',3'-oxide and 
subsequent swift conversion of the epoxide by epoxide hydro-
lase and/or glutathione S-transferases (3,4). Estragole can also 
be converted to 3'-hydroxyanethole that can be glucuronidated 
and excreted in urine (5) or oxidised to 4-methoxycinnamic 
acid and in a follow-up step form 4-methoxybenzoic acid. The 
main pathway for bioactivation of estragole proceeds by ini-
tial hydroxylation on the allyl side chain by cytochrome P450 
enzymes resulting in the formation of 1'-hydroxyestragole, the 
proximate carcinogenic metabolite. 1'-Hydroxyestragole can 
be detoxified by glucuronidation or via oxidation (4,6), the lat-
ter followed by glutathione conjugation. The glucuronidation 
of 1'-hydroxyestragole occurs in both humans and rats, being 
more dominant in rat than in human (7), whereas the oxidation 
of 1'-hydroxyestragole to 1'-oxoestragole has been demon-
strated to represent a major pathway in humans but not in rats 
(7). Alternatively, sulfonation of 1'-hydroxy estragole by sul-
fotransferases gives rise to the unstable metabolite 1'-sulfoox-
yestragole that decomposes to generate the reactive carbocation 
that covalently binds to DNA, RNA and protein (4,8). Several 
adducts are formed upon reaction of 1'-sulfooxyestragole with 
the guanine base in DNA including N2-(trans-isoestragol-3'-
yl)-2'-deoxyguanosine, N2-(estragole-1'-yl)-2'-deoxyguanosine, 
7-(trans-isoestragol-3'-yl)-2'-guanine and 8-(trans-isoestragol-
3'-yl)-2'-deoxyguanosine (4,9). The major guanine adduct 
formed is N2-(trans-isoestragol-3'-yl)-2'-deoxyguanosine (E-3'-
N2-dGuo) (Figure  1) that is considered to play a role in the 
genotoxic and carcinogenic effects induced by estragole (3,4). 
The dG modifications have generally been reported as major 
adducts formed upon reaction of electrophiles with DNA 
because dG is the most potent nucleophilic nucleoside that 
can efficiently react with electrophiles (10,11). Recently it was 
reported that adducts between estragole and adenine may also 
be formed to a significant extent (12).
Several investigators have studied the mechanism of estragole 
carcinogenesis by examining DNA binding and characterising 
DNA adducts formed by estragole in mouse models. Randerath 
et  al. (13) utilised 32P-postlabelling to analyse DNA adduct 
formation in the livers of adult female CD-1 mice administered 
intraperitoneal (ip) injections of estragole, safrole and other 
alkenylbenzenes. Estragole and safrole exhibited the strongest 
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binding to mouse liver DNA (200–300 pmol adduct/mg DNA, 
at a 10-mg dose). Phillips et  al. (14) found that estragole, 
methyleugenol and safrole formed adducts in liver DNA of 
newborn male B6C3F1 mice treated by ip injection on Day 1, 
8, 15 and 22 after birth at doses of 0.25, 0.5, 1.0 and 3.0 µmol 
per animal. At Day 23 upon dosing the adduct levels with 
methyleugenol (72.7 pmol/mg DNA) were higher than those 
with estragole (30.0 pmol/mg DNA) and safrole (14.7 pmol/
mg DNA) (14).
Recently, we defined a physiologically based biodynamic 
(PBBD) model to predict the dose-dependent DNA binding of 
estragole in rat liver (15) by extending the previously published 
physiologically based biokinetic (PBBK) model for rat (16). The 
PBBD model predicts the DNA adduct formation in the liver of 
rats at variable doses of estragole based on in vitro and in silico 
data only. However, the performance of the PBBD model devel-
oped could at the time not be evaluated due to the lack of in 
vivo data on DNA adduct formation in rats exposed to estragole. 
As detailed above, DNA adduct formation in vivo has to date 
only been studied in mice treated with estragole (13). Therefore, 
the objective of this study was to quantify the dose-dependent 
estragole–DNA adduct formation in rat liver and the urinary 
excretion of 1'-hydroxyestragole glucuronide in order to validate 
our PBBD model. The results obtained provide the first data set 
available on estragole–DNA adduct formation in rats and con-
firm DNA adduct formation in the metabolically active organs 
such as liver, lung and kidney, and also indicate that DNA adduct 
formation in the liver of estragole-exposed rats can be modelled 
within one order of magnitude accuracy using PBBD modelling.
Methods and materials
Materials
Estragole was obtained from Acros Organics (Geel, Belgium). 
2'-Deoxyguanosine was purchased from Sigma (Basel, Switzerland). 
1,2,3,7,9-15N
5
-2'-Deoxyguanosine (15N
5
-dGuo) was obtained from Cambridge 
Isotope Laboratories (Cambridge, MA). Alamethicin, β-glucuronidase, metha-
nol, zinc sulphate (heptahydrate), phosphodiesterase I from Crotalus adaman-
teus (venom phosphodiesterase), phosphodiesterase II from bovine spleen 
(spleen phosphodiesterase), uridine 5'-diphospho-glucuronic acid (UDPGA) 
and alkaline phosphatase were purchased from Sigma (Schnelldorf, Germany). 
Acetonitrile, formic acid, dichloromethane, hydrochloric acid (37%), sodium 
carbonate, ammonium bicarbonate, sodium sulphate, petroleum ether, ethyl 
acetate, sodium acetate, tris(hydroxymethyl)aminomethane (Tris), ethyl-
enediamine tetra acetic acid (EDTA), ammonia 30% and ethanol were pur-
chased from Merck (Darmstadt, Germany). Nuclease P1 was obtained from 
MP Biochemicals (Aurora, OH). Triethylacetate ammonium buffer, acetic 
anhydride and pyridine were purchased from Fluka (Buchs, Switzerland) and 
β-glucuronidase was purchased from Roche (Mannheim, Germany). Heparin 
lithium tubes were purchased from Gosselin (Borre, France). Carboxymethyl 
cellulose (CMC; sodium salt, low viscosity—42.0 mPa s) was purchased 
from Calbiochem. Animal feed Teklad 2914C was purchased from Harlan 
Laboratories.
Synthesis of E-3'-N2-deoxyguanosine (E-3'-N2-dGuo) and (15N
5
) E-3'-
N2-deoxyguanosine [(15N
5
) E-3'-N2-dGuo] was carried out as reported in Paini 
et al. (15).
Determination of kinetic constants for glucuronidation of 
1'-hydroxyestragole
Incubation with different batches of male Sprague Dawley rat liver S9 
were performed to determine the Vmax and Km for glucuronidation of 
1'-hydroxyestragole (OHES). Three batches were purchased from BD 
Bioscience (cat 452591 pooled Sprague Dawley rat liver S9—Batch 1: Lot 
61642; Batch 2: Lot 74099; Batch 3: Lot 88875). The incubations were 
performed as previously described (16) using a final volume of 200  µl, 
Fig. 1. Metabolism of estragole [adapted from Punt et al. (7)].
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containing (final concentrations) 10 mM UDPGA and 0.2 mg/ml S9 protein 
in 0.2 M Tris–HCl (pH 7.4) containing 10 mM MgCl
2
. The incubation mix-
ture was pretreated on ice for 15 min with 0.025 mg/ml (final concentration) 
of alamethicin added from a 200 times concentrated stock solution in metha-
nol (17,18). The incubation reactions were started after pre-incubation of 
1 min by the addition of 1'-OHES at final concentrations varying from 50 
to 2000 µM added from 200 times concentrated stock solutions in dimethyl-
sulfoxide (DMSO). The incubations were carried out for 10 min at 37°C and 
terminated by adding 50 µl of cold acetonitrile. Blank incubations were per-
formed without the cofactor UDPGA. 1'-Hydroxyestragole glucuronide was 
quantified by high-performance liquid chromatography (HPLC). Samples 
were centrifuged (16  000g for 5 min) and 50 µl of each supernatant were 
injected on an Alltima C18 5u column, 150 × 4.6 mm (Grace Alltech, Breda, 
The Netherlands) coupled to a HPLC-DAD system: a Waters 2695 Alliance 
system with a Waters 2996 photodiode array detector (Waters, Etten-Leur, 
The Netherlands). The gradient was made with ultrapure water containing 
0.1% of acetic acid and acetonitrile. The flow rate was set at 1 ml/min and a 
linear gradient was applied from 10 to 25% of acetonitrile over 30 min, after 
which the percentage of acetonitrile was increased in 2 min to 100% and kept 
at 100% for 2 min. 1'-OHES glucuronide and 1'-OHES were quantified using 
a calibration curve of 1'-OHES recorded at a wavelength of 225 nm. For each 
batch Vmax and Km were determined in duplicate. The final Vmax and Km 
were calculated as the average of the three newly determined values and two 
data sets previously reported in the literature (16,19).
Physiologically based biodynamic modelling
The PBBD model was developed based on the PBBK model developed by 
Punt et al. (16) and described in detail previously (15) (Figure 2). As presented 
in the Results some PBBK model parameters were defined specifically for 
this study, including the parameters for body weight and organ weights that 
were based on the actual data obtained for the rats of this study. The kinetic 
parameters for glucuronidation of 1'-OHES were defined in more detail using 
different batches of liver microsomes. The kinetics of 1'-OHES glucuroni-
dation appeared to have a major impact on the PBBK/BD model outcomes 
and previous studies revealed a significant variation for these kinetic param-
eters (7,16,19). Other parameters were kept similar to those reported and used 
before (7,19). It is important to note that the PBBD model is able to predict 
DNA adduct formation in the liver, the target organ, but not in kidney and 
lungs although these organs were included in the experimental analysis of 
DNA adduct formation in vivo.
To further improve the overall simulation of DNA adduct formation by the 
in vitro PBBD model, and to further reduce the differences between predicted 
and experimentally observed values, a refined PBBD model was defined taking 
two additional factors into account:
1. Liver zonation dividing the liver compartment within the PBBD model into 
three equal zones: The liver architecture in vivo is not as homogenous as 
hepatocytes cultured in vitro. The heterogeneity of the liver implies that 
relevant biotransformation enzymes may be expressed in different parts of 
the organ to a different extent (20). The liver is mainly divided in a peri-
portal zone (Zone 1), a mid-zone (Zone 2) and a perivenous zone (Zone 3). 
From the literature it can be derived that the enzymes involved in estragole 
hydroxylation in humans are CYP1A2, CYP2A6 and CYP2E1 (21). In rats, 
CYP2E1 and CYP1A2 are comparable to human CYP2E1 and CYP1A2, 
however, CYP2A6 in humans is comparable to CYP2A1/2 in rats (22). 
All these rat CYPs are more active in the perivenous zone of the liver as 
compared with the other zones (23). UDP glucuronosyltransferase (UGTs) 
are expressed in the perivenous zone (20,24) but also in the periportal zone 
(25,26). SULT enzymes are expressed preferentially in the periportal zone 
(20,24). To accommodate both possible locations of the UGTs two zonal 
models were described one with the UGTs in the perivenous zone (Zone 
3) and another with the location of the UGTs in the periportal zone (Zone 1).
2. A submodel for 1'-OHES: Because the zonal models imply that upon its 
formation by CYPs in Zone 3 1'-OHES has to enter the systemic circulation 
before it can enter the liver in Zone 1 where sulfonation by SULTs or—in 
the second approach—glucuronidation by UGTs will take place, a sub-
model for the estragole metabolite 1'-OHES was added to the PBBD model, 
allowing the metabolite to enter the systemic circulation before its further 
conversion. Furthermore, given that systemic distribution of 1'-OHES will 
also provide possibilities for its conversion by extrahepatic metabolism we 
allowed—as a first approximation—only 60% of the 1'-OHES formed in 
Zone 3 to re-enter the liver. The value of 60% was based on the fact that the 
relative amount of DNA adduct formation in liver, lung and kidney indi-
cated that at least for the SULT-mediated bioactivation of 1'-OHES ~60% 
occurred in the liver, the other part occurring in kidney (~5%) and lungs 
(~35%) (see Results).
The new PBBD model is graphically depicted in Figure 3. The Supplementary 
File, available at Mutagenesis Online presents the equations for this refined 
PBBD model.
Animals
The animal studies were in compliance with the Dutch Act on animal 
experimentation (Stb, 1977, 67; Stb 1996, 565), revised February 5, 1997. 
The study was approved by the ethical committee on animal experimenta-
tion of Wageningen University. All procedures were considered to avoid and 
minimise animal discomfort. Male Sprague Dawley rats, 6 weeks old, were 
purchased from Harlan laboratories (The Netherlands). Rats were housed in 
type IV cages with Lignocel bedding (Lignocel BK 8/15), accommodating 
three rats per cage. Enrichment was provided, i.e. paper tissue, for each cage. 
Animal cages were cleaned according to the standard protocols. A photoper-
iod of 12-h light/dark cycle for the rats was applied during the animal acclima-
tization period and treatment period. Temperature (21°C ± 1°C) and humidity 
(55 ± 10%) were monitored daily. Teklad 2914C pellet feed and tap water were 
provided ad libitum during the overall period of the study (from arrival at the 
facility to sacrifice).
Time-response study
The total number of animals for the time-response study was 25 white male 
outbred Sprague Dawley rats, 6 weeks old (174 g; SD ± 6). Upon arrival, 
animals were split randomly into cages and weighed 24 h after arrival at the 
facility, 7 days after arrival and 12 days after arrival. After a 12-day acclima-
tization period in type IV cages in groups of three animals per cage, animals 
were put into metabolic cages 24 h prior to gavage and were kept in the meta-
bolic cages up to time of sacrifice. Animals were treated with a single dose of 
estragole of 300 mg/kg bw by gavage using a solution of estragole of 130 mg/
ml in 0.5% CMC (0.5 g of CMC in 100 ml of distilled water), with the volume 
of gavage not exceeding 10 ml/kg. Animal average weight was 242.3 g (SD 
± 9.5) at treatment and 241.3 g (SD ± 10.9) at sacrifice. After treatment ani-
mals were sacrificed at 2, 6, 24 or 48 h. For the 48-h time point a control was 
also introduced with five rats receiving only the vehicle control 0.5% CMC. 
Anaesthesia was done with a mixture of isoflurane and oxygen, blood was 
removed after which the liver was harvested, weighed and cut into pieces, 
snap frozen in liquid nitrogen and stored at −80°C until further processing.
Dose-response study
The total number of animals for the dose-response study was 60 white 
male outbred Sprague Dawley rats, 6 weeks old (177.1 g; SD ± 4.4). Upon 
arrival animals were split randomly into cages and weighted 24 h after arrival 
at the facility, 7 days after arrival and 12 days after arrival. After a 12-day 
Fig. 2. Original schematic diagram of the proposed PBBK/BD model for 
estragole by Punt et al. (16).
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acclimatization period in type IV cages in groups of three animals per cage, 
animals were put into metabolic cages 24 h prior to gavage and were kept in 
the metabolic cages up to time of sacrifice. The following doses were admin-
istered once to the rats: 0 mg/kg bw (vehicle control 0.5% CMC), 5, 30, 75, 
150 or 300 mg/kg bw of estragole using a solution of estragole of 2.5, 15, 37, 
76 and 150 mg/ml in 0.5% CMC, respectively. The volume of gavage did not 
exceed 10 ml/kg. Urines were collected twice a day (morning and afternoon) 
and were stored at −80°C until further analysis. Rats were sacrificed after 
48 h. Average weight at treatment was 255.3 g (SD ± 9.8) and at sacrifice it 
amounted to 263.0 g (SD ± 10.23). After anaesthesia of the animals with a 
mixture of isoflurane and oxygen, blood was removed and then liver, kidney 
and lungs were harvested, weighed and cut into pieces, snap frozen in liquid 
nitrogen and stored at −80°C until further processing. Blood was collected 
before removing organs in heparin tubes (4 ml), kept on ice and centrifuged 
(2000 rpm for 20 min, Sigma 2D centrifuge) and plasma was stored at −80°C 
in aliquots for further analysis.
Tissue DNA extraction and digestion
DNA was extracted from liver, kidney and lungs using the Get pure DNA 
Kit-Cell protocol (Dojindo Molecular Technology Inc., Kumamoto, Japan) 
for tissue (following the manufacturer’s instructions). Briefly, three samples 
of each tissue were taken randomly from all organs, around 50–100 mg of 
each organ were put into a 2 ml eppendorf tube, and 800 µl of the lysis buffer 
with 20  µl of proteinase K solution were added. Homogenisation of tissue 
was done using a Fast Prep cell disruptor instrument. The homogenised sam-
ples were further processed following the manufacturer’s protocol (Dojindo 
Molecular Technology Inc., Kumamoto, Japan). The final DNA pellet was 
dissolved in 100 µl MilliQ water. The yield and purity of the extracted DNA 
was determined using the Nanodrop technique by measuring the absorbance 
ratio A260 nm/A280 nm. DNA samples with an absorbance ratio of 1.8–2 were 
considered sufficiently pure. The quantity of DNA per sample was calculated 
from the Nanodrop output in ng/ml using a molar extinction coefficient for 
double-stranded DNA of 50 (L × mol−1cm−1). The method of digestion was 
modified from Delatour et  al. (27) for the release of the nucleosides E-3'-
N2-dGuo. Briefly, per 50 µg of DNA in 100 µl of water, 20 µl of buffer P1 
(300-mM sodium acetate, 1-mM ZnSO
4
, pH 5.3), 12 µl of spleen phospho-
diesterase solution (0.0004 U/µl in water) and 10 µl of nuclease P1 (0.5 µg/µl 
in water) were added and the resulting solution was incubated for 4 h at 37°C. 
Following incubation, 20 µl of PA buffer (500 mM Tris–HCl, 1 mM EDTA, pH 
8.0), 13 µl of venom phosphodiesterase solution (0.00026 U/µl in water) and 
5 µl of alkaline phosphatase (0.764 U/µl in water) were added and the mixture 
was incubated for 3 h at 37°C (15,25). The hydrolysed sample was evaporated 
to dryness and reconstituted in 50 µl of water.
Isotope dilution quantification of E-3'-N2-dGuo
Quantification of the nucleoside E-3'-N2-dGuo by isotope dilution was done 
as reported in Paini et al. (15). Briefly, 50 µl of digested DNA from rat tissue 
were spiked with 10 µl of the internal standard (15N
5
) E-3'-N2-dGuo to achieve 
5 ng (0.012 nmol) injection of the internal standard into the instrument using an 
injection volume of 10 µl. In order to quantify the amount of adduct formed in 
the samples, a calibration curve was prepared using increasing concentrations 
of E-3'-N2-dGuo with a constant concentration of (15N
5
) E-3'-N2-dGuo.
LC–MS/MS method for detection and data analysis of E-3'-N2-dGuo
LC–MS/MS analysis was performed on a Perkin Elmer 200 Series HPLC 
System (Perkin Elmer, Waltham, MA) coupled to a API 3000 system (Applied 
Biosystem, Foster City, CA). Samples were injected on an Agilent Zorbax 
Extend-C18 column, 2.1 × 50 mm, 3.5 Micron 80 Å (Basel, Switzerland), with 
a Zorbax guard column. The gradient was made with ultrapure water containing 
0.1% (v/v) formic acid and 100% acetonitrile. The flow rate was set at 0.3 ml/
min. A  linear gradient was applied from 10 to 50% acetonitrile over 3 min, 
after which the percentage of acetonitrile was brought to 100% in 1 min, and 
kept at 100% acetonitrile over 2 min. The amount of acetonitrile was lowered 
to 10% over 1 min, and the column was equilibrated at these initial conditions 
for 8 min. E-3'-N2-dGuo eluted at 2.88 min. The mass spectrometric analysis 
was performed with the following settings: Nebuliser gas (air) was set at 15 
psi, Curtain gas (nitrogen, which is used to keep the analyser region clean) was 
set at 10 psi, ion spray voltage was 4700 V, collision energy (CE) was 15 eV, 
ion source temperature was set at 300°C, declustering potential was set at 37V, 
focusing potential was set at 200V, entrance potential at 9 V and collision cell 
exit was set at 12 V. Nitrogen was used as sheath gas turbo, ion spray, with a 
pressure of 7000 l/h. The dwell time per transition was 0.05 sec. A divert valve 
was used in order to discard the gradient after elution of the peak. Quantification 
of the DNA adduct was carried out using selected-ion detection in the multi-
ple reaction-monitoring (MRM) mode, recording the following characteristic 
transitions—for the E-3'-N2-dGuo: 414 m/z → 298 m/z (CE = 18 eV); 414 m/z 
→ 164 m/z (CE  =  37 eV); and 414 m/z → 147 m/z (CE  =  40 eV); for the 
Fig. 3. Schematic diagram of the new proposed PBBK/BD model for estragole in rodents, with a 1'-OHES submodel and the liver compartment (L) subdivided 
into three equal zones: L1. A periportal zone containing the sulfotransferase (SULTs) activity and glucuronsyltransferases (UGTs). L2. A middle zone modelled 
without relevant enzyme activity. L3. A pericentral zone including the CYPs and glucuronsyltransferases (UGTs). GI, gastro intesintal tract; RPT, rapidly 
perfused tissue; SPT, slowly perfused tissue.
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(15N
5
) E-3'-N2-dGuo: 419 m/z → 303 m/z (CE = 18 eV); 419 m/z → 169 m/z 
(CE = 37 eV). Figure 4 shows the chromatograms of the E-3'-N2-dGuo (414 → 
298, quantifier) adduct formed in the three organs 48 h after a dose of 300 mg/
kg bw, along with the qualifier transition (414 → 164) and the peak of (15N
5
) 
E-3'-N2-dGuo (419 → 303).
Data analysis of the calibration series and sample sequence was performed 
using Analyst software (Applied Biosystem) and integrated using an Excel 
spreadsheet developed internally (Nestlé Research Center), to comply with 
EU guidelines 2002/657/EC concerning the performance of analytical methods 
and the interpretation of results (EU guidelines: 2002/657/EC). The amount 
of E-3'-N2-dGuo detected in the samples was related to the total amount of 
digested DNA detected in each sample and adjusted for the average molecular 
weight of DNA monophosphorylated nucleotides (nt) of 327 g/mol, in order to 
quantify the number of E-3'-N2-dGuo adducts per 1000 nucleotides. For sam-
ples resulting in a negative value or below the Limit of Detection (LOD) a 
zero value was applied; and for samples resulting in a value below the Limit of 
Quantification (LOQ), the LOD value was applied.
Quantification of urinary excretion of 1'-hydroxyestragole glucuronide
Preparation and analysis of urines were done following the protocol reported 
by Zeller et  al. (28). Urines were analysed, randomly for eight rats for each 
dose group. The vehicle control group was not analysed, since for each rat a 
urine sample was collected 24 h before treatment that served as control. Briefly, 
to 50µl urine sample 10 µl β-glucuronidase (0.36 U, 145  700 U/ml) in phos-
phate buffer (pH 5)  were added. Samples were incubated at 37°C for 2 h. 
Subsequently the metabolites were extracted using 500 µl ethylether (twice), the 
sample thus obtained was centrifuged and transferred to a new Eppendorf tube, 
after which the sample was dried using a speed vacuum and reconstituted with 
200 µl water. An isotope dilution technique was used to measure the amount 
of 1'-OHES released from 1'-OHES glucuronide compared with the internal 
standard D-1'-hydroxyestragole (26). D-1'-hydroxyestragole was prepared by 
AltanChim Pharma (Nantes, France). LC–MS/MS analysis was performed on a 
Perkin Elmer 200 Series HPLC System (Perkin Elmer, Waltham, MA) coupled 
with an API 3000 system (Applied Biosystem, Foster City, CA). Samples were 
injected on an Agilent Zorbax Extend-C18 column, 2.1 × 50 mm, 3.5 Micron 
80  Å (Basel, Switzerland), with a Zorbax guard column. The gradient was 
made with ultrapure water containing 0.1% (v/v) formic acid and 100% ace-
tonitrile. The flow rate was set at 0.3 ml/min. A linear gradient was applied from 
10 to 50% acetonitrile over 3 min, after which the percentage of acetonitrile 
was brought to 100% in 1 min, and kept at 100% acetonitrile over 2 min. The 
amount of acetonitrile was lowered to 10% over 1 min, and the column was 
equilibrated at these initial conditions for 8 min. 1'-Hydroxyestragole eluted at 
3.30 min. The mass spectrometric analysis was performed with the following 
settings: Nebuliser gas (air) was set at 15 psi, Curtain gas (nitrogen, which is 
used to keep the analyser region clean) was set at 12 psi, ion spray voltage of 
2200 V, collision energy (CE) of 15 eV, ion source temperature at 300°C, declus-
tering potential was set at 28 V, focusing potential was set at 200 V, entrance 
potential at 12 V and collision cell exit was set at 27 V. Nitrogen was used as 
sheath gas turbo, ion spray, with a pressure of 7000 l/h. The dwell time per tran-
sition was 0.05 sec. A divert valve was used in order to discard the gradient after 
elution of the peak. Quantification of the 1'-hydroxyestragole was carried out 
using selected-ion detection in MRM mode recording the following character-
istic transitions—for 1'-hydroxyestragole: 147.2 m/z → 91.1 m/z (CE = 18 eV); 
147.2 m/z → 115.1 m/z (CE = 37 eV); 147.2 m/z → 131.2 m/z (CE = 40 eV); 
for D-1'-hydroxyestragole: 150.2 m/z → 93.1 m/z (CE = 18 eV); 150.2 m/z → 
118.1 m/z (CE = 37 eV); 150.2 m/z → 134.2 m/z (CE = 40 eV).
Statistical analysis
A t-test was performed using Excel (Microsoft Office 2010). Correlation analy-
sis was performed using GraphPad Prism 5 (Version 5.04, 2010; GraphPad 
Software, Inc.). Vmax and Km were obtained using Graph pad Prism 5 (La 
Jolla, CA), by selecting XY analyses—nonlinear regression and fitting the data 
to the standard Michaelis–Menten equation.
Results
Refinement of the PBBD model
In order to validate the PBBD model the in vivo study was 
performed in two steps: first, a time-response study was car-
ried out to determine the time point at which the level of DNA 
adducts in the target organ (liver) was maximal. Following this 
time-dependent study a dose-response study was performed 
using the time point determined in the first study, characteris-
ing the dose-dependent formation of DNA adducts in the liver 
and non-target organs (kidney and lungs) as well as the level of 
urinary excretion of 1'-OHES glucuronide.
Previously, we developed a PBBD model for estimation of 
in vivo estragole–DNA adduct formation based on experimen-
tal data on DNA adduct formation in primary hepatocytes (15). 
Fig. 4. Chromatograms representing the E-3'-N2-dGuo adduct formed in liver, kidney and lungs at the quantifier transition (414 → 298), qualifier transition 
(414 → 164) and the peak of the internal standard (15N
5
) E-3’-N2-dGuo (419 → 303). The highlighted peak reflects the presence of the adduct.
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This PBBD model allows estimation of the level of DNA adduct 
formation especially in rat liver after different doses of estragole. 
To make the PBBD model as accurate as possible some adjust-
ments were made to the model previously described. These 
included first of all a precise definition of the body and organ 
weights taking into account the actual values of the male Sprague 
Dawley rats used in this study. Previously we applied as average 
body weight for male rats 250 g, and values for liver, kidney and 
lung weight of 8.5 g, 1.75 g and 1.25 g, respectively (15,16). In 
this study, the average body weight (for 60 animals) amounted to 
263 g (SD ± 10.25) and the organ weights were 11.32 g (±0.75), 
1.70 (±0.14) and 1.42 (±0.09) for liver, kidney and lung, respec-
tively. Furthermore, the PBBD model published (15) was run for 
2 h that was extended to 24 or 48 h, respectively, in this study in 
order to make a correct comparison with the in vivo experimental 
data, since 24 h was the time used for urine collection and 48 h 
was the time between dosing and sacrifice used in the in vivo 
DNA adduct dose-response study. The second improvement was 
that the kinetic parameters Km and Vmax for glucuronidation 
of 1'-OHES were quantified for different batches of liver micro-
somes (Table I). This was done because the sensitivity analysis 
of the model previously indicated these parameters to be of sig-
nificant influence on the outcomes obtained (15), whereas they 
appeared to vary with the experimenter and with the batch of 
liver microsomes analysed (7,16,19) as shown in Table I. The 
average of five batches of male liver microsomes (three analysed 
and two obtained from the References 7,19) resulted in values 
for the kinetic parameters for glucuronidation of 1'-OHES that 
amounted to a Vmax of 51.5 nmol/min (SD ± 56) [(mg S9 pro-
tein)−1] and a Km of 203.4 µM (SD ± 40) (Table I). These values 
were incorporated in the present PBBD model.
Time-dependent DNA adduct formation in vivo
Levels of DNA adducts in Sprague Dawley rats exposed by oral 
gavage to 300 mg/kg bw of estragole were measured in liver 
over time up to 48 h. Six random parts of each liver (50–100 mg) 
were used to extract the E-3'-N2-dGuo adduct. The limit of 
detection of the adduct in the liver was 0.001 adduct/1000 nt 
(1 in 106 nt). Figure 5 shows the DNA adduct formation in liver 
over time after a dose of 300 mg/kg bw, which was found to 
be time dependent. The amount of adduct formed in the liver 
at 48 h was significantly higher (P = 0.003 by t-test) than the 
amount formed at 24 h. No adducts were detected in the control 
group, confirming that adduct formation is treatment related. 
Based on the results obtained 48 h post dosing was selected as 
the time point for analysis of DNA adduct formation in the sub-
sequent dose-response study.
Dose-dependent DNA adduct formation in vivo
Levels of DNA adducts in male Sprague Dawley rats exposed 
once by oral gavage to increasing doses (0, 5, 30, 75, 150 and 
300 mg/kg bw) of estragole were measured in liver, kidney and 
lungs 48 h after dosing (Figure 6). In the Supplementary File, 
available at Mutagenesis Online values for individual rats are 
reported, the results show for each dose group high variability 
between individuals. The limit of detection of the adduct was 
0.001 adduct/1000 nt (1 in 106 nt) for liver and kidney, and 
0.004 adduct/1000 nt (4 in 106 nt) for lung. In the liver a clear 
dose-dependent increase in E-3'-N2-dGuo formation was found 
(Figure 6A). The level of DNA adducts detected 48 h after a dose 
of 300 mg/kg bw in this experiment can be compared with the 
value obtained in the time-response experiment. This revealed 
for the level of DNA adduct detected in the liver a somewhat 
higher amount of DNA adducts detected in the time-response 
experiment, amounting to 0.28 (SD ± 0.20) adducts/1000 nt 
(Figure 5) versus 0.10 (SD ± 0.08) adducts/1000 nt (Figure 6A) 
detected in the dose-response experiment, but the difference 
was not statistically significant. In lungs, DNA adducts were 
detected only at the two highest doses of estragole of 150 mg/kg 
bw and 300 mg/kg bw (Figure 6B). In kidney a dose response 
in DNA adduct formation was not observed, and levels were 
highest at the two highest dose levels (Figure 6C), with a stat-
istically significant difference compared with the lower doses. 
At 300 mg/kg bw the amount of DNA adducts in the liver was 
9 times higher than in kidney and 5 times higher than in lungs.
Comparison of the in vivo urinary excretion of 
1'-hydroxyestragole glucuronide to the levels predicted by 
the PBBD model
Urine was collected in order to measure 1'-OHES glucu-
ronide excretion and validate the outcomes of the PBBD 
Table I. Kinetic parameters for 1'-OHES glucuronide formation 
Kinetic parameters Punt et al. (7) Al-husainy et al. (19) Batch 1 Batch 2 Batch 3 Average AverageAll
Vmax [nmol min−1 (mg S9 protein)−1] 7.0 151 32.55 34.59 32.62 33.25 51.5
Km (µM) 137 241 201.2 211.1 226.7 209.5 203.4
Source: From References (7,19) and from experimental results using several batches of pooled male SD S9 fraction. The Vmax and Km values, average all, 
marked in bold were used for the simulation with the PBBD model.
Batches were purchased at BD Bioscience (cat 452591 pooled Sprague Dawley rat liver S9), for each batch the values are the average of two technical replicates. 
Batch 1: Lot 61642; Batch 2 : Lot 74099; Batch 3: Lot 88875.
Fig. 5. Time-dependent DNA adduct formation in liver. DNA adducts are 
expressed as number of adducts in 1000 nt. A t-test was used to test for 
significant difference in maximal DNA adduct formation between  0 and 48 h 
(*** P <0.001) and between 24 and 48 h groups (** P <0.01); data represent 
the average and standard deviation of five rats, from which three technical 
replica were done.
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model predicting the dose-dependent formation of this 
urinary metabolite. In the Supplementary File, available at 
Mutagenesis Online the urinary excretion of the 1'-OHES 
glucuronide measured for each dose group for eight individ-
ual rats from 0 to 24 h and from 0 to 48 h is reported. The 
results show for each dose group high variability between 
rats in excretion of the metabolite 1'-OHES glucuronide. 
Further, the results show a dose-dependent increase of 
1'-OHES glucuronide in urine. For each dose the cumula-
tive amount of 1'-OHES glucuronide formed was calculated 
by the PBBD model. Figure  7 shows the results obtained 
and also presents the data previously reported for urinary 
excretion of 1'-OHES glucuronide by estragole-exposed 
female Wistar albino rats by Anthony et al. (5). The results 
obtained reveal that our data obtained for estragole-exposed 
male Sprague Dawley rats match those reported by Anthony 
et al. (5) for female Wistar albino rats. The results also reveal 
that the PBBD model–based predictions at 24 h upon dosing 
match the experimentally observed values within less than 
an order of magnitude since their predicted levels were 4.6–
7.7-fold higher than the urinary levels actually observed.
Comparison of the in vivo results obtained to the levels of 
DNA adduct formation predicted by the PBBD model
Figure  8 presents a comparison between the dose-dependent 
formation of estragole–DNA adducts in the liver of male 
Sprague Dawley rats as experimentally determined in this study 
and as predicted by the PBBD model. The results reveal that 
the PBBD model–based predictions closely match the experi-
mentally observed values. The PBBD model predictions at 48 h 
upon dosing appear to slightly overestimate DNA adduct for-
mation by a factor of 1.9–2.3-fold.
Correlation of DNA adduct formation and the urinary 
biomarker 1'-hydroxyestragole-glucuronide
Figure  9 displays the relation between the number of DNA 
adducts formed (# adduct/1000nt) in liver and the amount of 
1'-OHES (nmol/kg bw) excreted in urine as glucuronide conju-
gate. A significant positive correlation was found with increas-
ing estragole dose between the number of DNA adducts and the 
concentration of 1'-OHES glucuronide in the urine after 48 h 
(R2 = 0.90; Pearson coefficient p = 0.95; P = 0.0118; n = 5 data 
points each representing the average of eight rats).
Additional refinement of the PBBD model
To further improve the overall prediction of 1'-OHES glucu-
ronide and DNA adduct formation by the model, a refined 
PBBD model was defined including division of the liver com-
partment in three equal zones (liver zonation) and the creation 
of a separate submodel for the estragole metabolite 1'-OHES, 
Fig. 6. Dose-dependent DNA adduct formation in liver (A), kidney (B) and 
lungs (C), DNA adducts are expressed as number of adducts in 1000 nt. 
A t-test was used to test for significant difference between treatment groups 
versus control group (*P < 0.05, **P < 0.01, ***P < 0.001); data represent 
the average and standard deviation of 10 rats, from which 3 technical replica 
were done.
Fig. 7. PBBD model predicted (solid line) and experimentally determined 
24 h urinary levels of 1'-OHES glucuronide at increasing oral doses of 
estragole. Data presented as black squares are the results of this study whereas 
those presented as open circles are those reported by Anthony et al. (5) for 
female Wistar albino rats. Data represent the average and standard deviation 
of eight rats.
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allowing only 60% of the 1'-OHES to re-enter the liver. This 
modification of the model reflects that the liver architecture 
in vivo is not homogenous; furthermore extrahepatic circula-
tion of 1'-OHES may increase the chances on its conversion 
by extrahepatic enzymes reducing the chances on its conver-
sion to a DNA reactive metabolite in the liver. Figure 3 pre-
sents a schematic overview of the refined model. The liver 
was described as three equal zones as explained in Manning 
et al. (20), where each zone differs in the overall expression 
of the enzymes involved in the metabolism of estragole and 
1'-OHES. The activity of each enzyme was confined to only 
the specific zone where it is most highly expressed, with 
exception of the UGTs that were modelled in either Zone 1 or 
Zone 3. Figure 10A and 10B present the results obtained with 
the two new zonal models as compared with the predictions 
based on the original model and the experimental data. The 
results presented for DNA adduct formation in Figure  10A 
reveal that the predictions obtained using the refined model 
with the liver zonation and the submodel for 1'-OHES with 
glucuronidation in Zone 3 results in predictions that match 
the in vivo experimental values even better than the original 
model (Figure 10A, black dashed line). For the glucuronida-
tion a slight improvement occurred compared with the origi-
nal model (in Figure 10B the two lines coincide) and predicted 
data were generally 4–6-fold different from the experimental 
data (Figure 10B, black dashed line). In a second approach 
glucuronidation was modelled in Zone 1. The predicted DNA 
adduct formation matched the experimental data to a lower 
extent was 11-fold overpredicted (Figure  10A, grey dashed 
line; note the y-axis is a log scale). However, for the formation 
of 1'-OHES glucuronide predicted values matched the experi-
mental data to a better extent with the deviation between pre-
dicted and experimental values being on average 2.8–5-fold 
(Figure 10B, grey dashed line).
It is important to note as well that in the refined models the 
full conversion of estragole takes more time reflected by a 
Fig. 8. In vitro PBBD model (solid line) prediction of the DNA adduct 
formation at 48 h versus DNA adducts measured in vivo (black square) at 
different oral doses of estragole. Data represent the average and standard 
deviation of 10 rats.
Fig. 9. Correlation between 1'-OHES glucuronide urinary excretion and 
estragole DNA adducts in the liver at increasing estragole doses (R2 = 0.90; 
Pearson coefficient p = 0.95; P = 0.0118; n = 5 data points each representing 
the average of eight rats).
Fig. 10. (A) Comparison of experimental data obtained in this study for 
DNA adduct formation in the liver to their PBBK/PBBD−based predicted 
values when using either the original model (black lines) or the newly defined 
extended PBBK/PBBD models including liver zonation and a submodel for 
1'-hydroxyestragole; (dashed lines). The two zonal models include UGTs 
in either Zone 3 (dashed black line) or Zone 1 (dashed grey line) and in 
vivo experimental data are presented as black triangles and represent the 
average and standard deviation of 10 rats. (B) Comparison of experimental 
data obtained in this study for formation of urinary 1'-hydroxyestragole 
glucuronide to their PBBK/PBBD−based predicted values when using either 
the original model (black lines) or the newly defined extended PBBK/PBBD 
models including liver zonation and a submodel for 1'-hydroxyestragole; 
(dashed lines). The two zonal models include UGTs in either Zone 3 (dashed 
black line) or Zone 1 (dashed grey line). Data presented as black squares are 
the results of this study whereas those presented as open circles are those 
reported by Anthony et al. (5) for female Wistar Albino rats. Urinary data 
(black squares) represent the average and standard deviation of eight rats.
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continued increase in the amount of DNA adduct formation up 
to at least 30 h upon dosing 300 mg estragole/kg bw, which was 
20 h in the original model without liver zonation.
Discussion
The aim of this study was to quantify dose-dependent 
estragole–DNA adduct formation in male Sprague Dawley rat 
liver and the levels of urinary excretion of 1'-hydroxyestragole 
glucuronide in order to validate the in vitro PBBD model previ-
ously built (15). The adduct measured and predicted in this was 
E-3'-N2-dGuo, which was previously reported to be the most 
abundant adduct formed by estragole (10,11). Recently it was 
reported that adducts between estragole and adenine may also 
be formed to a significant extent (12). However, the formation 
of additional adducts to the E-3'-N2-dGuo taken into account in 
this study will not affect the outcomes of this study since our 
measurements and the PBBD predictions focused on formation 
of E-3'-N2-dGuo only within the liver.
The first validation step of the PBBD model in this study 
was based on the dose-dependent urinary excretion of 1'-OHES 
glucuronide. The results acquired reveal that our data obtained 
for estragole-exposed male Sprague Dawley rats match those 
reported by Anthony et  al. (5) for female Wistar albino rats. 
The results also reveal that the PBBD model–based predictions 
match the experimentally observed values within less than an 
order of magnitude. Differences between the present data and 
those reported by Anthony et al. (5) may be caused by differ-
ences in the animal strain and sex. Animals used in Anthony 
et al. (5) study were female Wistar albino rats and those in this 
study male outbred Sprague Dawley rats. The PBBD model 
predicted somewhat higher levels of the 1'-OHES glucuronide 
compared with in vivo data, which was also found previously by 
Punt et al. (16), but deviations were generally within one order 
of magnitude. Given this result it is important to stress that devi-
ations within one order of magnitude are generally considered 
acceptable within the present state-of-the-art of PBBK model-
ling (29). One explanation for the deviation in predicted urinary 
levels of 1'-OHES glucuronide could be that the actual bioavail-
ability of estragole is lower than 100%. Another reason could be 
that in the present PBBK model excretion and further extrahe-
patic metabolism of 1'-OHES are not included, which may result 
in some overestimation of the levels of 1'-OHES in the liver and 
thus of 1'-OHES glucuronide and 1'-sulfooxyestragole pre-
dicted to be formed, and subsequently of the predicted urinary 
levels of 1'-OHES glucuronide and DNA adducts formed. The 
match between experimentally observed and predicted values 
is also considered adequate when it is taken into consideration 
that the current PBBD model was based on in vitro data only, 
whereas most current physiologically based kinetic or dynamic 
models use in vivo data to optimise parameters in the model 
and improve the fit (30 and references therein). The PBBD pre-
dictions were obtained using data from primary hepatocytes 
exposed to 1'-OHES and this implies that the level of DNA 
adduct formation implicitly includes the balance between DNA 
adduct formation and DNA repair (15). DNA adducts are known 
to be a biomarker of genotoxic exposure and urinary excretion of 
metabolites are biomarkers of early biological effect (31). Thus, 
a comparison between the experimental data for cumulative uri-
nary excretion of 1'-OHES glucuronide and DNA adduct forma-
tion in the liver was made revealing a positive correlation. This 
suggests that with increasing dose of estragole a proportional 
increase in bioactivation occurs in the liver, which is reflected 
by an increased level of urinary excretion of 1'-OHES glucu-
ronide. In the second step, the PBBD model–based predictions 
for formation of estragole–DNA adducts in the liver of male 
rats were compared with the experimental data obtained. Using 
the optimised new parameters the PBBD model–based predic-
tions for the levels of adduct formation were within the same 
order of magnitude as the in vivo measurements. Data on DNA 
adduct levels in rats exposed to estragole have not been reported 
before. Thus the results of this study can only be compared 
with data obtained in estragole-exposed mice. Randerath et al. 
(13) reported in female CD-1 mice the formation of 1 adduct 
in 10 000–15 000 DNA nucleotides after a single ip injection 
of 10 mg estragole per mouse. Assuming a mouse weight of 
0.025 kg, the dose was estimated to be 400 mg/kg bw. At our 
highest dose tested in vivo (300 mg/kg bw) we obtained 1 adduct 
in 10 000 nucleotides that is comparable with the value reported 
by Randerath et al. (13) although this value was obtained using a 
different technique for quantification of the DNA adduct levels, 
in a different species and at a different dose level. The amount 
of E-3'-N2-dGuo adducts at a daily human exposure level of 
0.01 mg/kg bw/day (3) and 0.07 mg/kg bw/day estragole (32), 
was predicted to be 0.44 and 3.1, respectively, in 108 nt. These 
levels of adducts are orders of magnitude below the background 
level of DNA damage of 100 adduct in 108 nt, which have been 
suggested to be of no known consequence (33).
To further improve the PBBD-based predictions a refined 
PBBD model was developed. This was done by dividing the 
liver compartment in three equal zones (20), where Zone 1 was 
assumed to contain sulfotransferase (SULT) activity and Zone 
3 cytochrome P450 (CYP). The UGT enzymes were placed 
either in Zone 3 or in Zone 1, resulting in two zonal models. 
Furthermore, the refined models also included a submodel for 
1'-OHES, to allow for its entering the systemic circulation, and 
only 60% was allowed back into the liver. This approach can 
be seen as a ‘dilution factor’ in time of the metabolite within 
the body increasing the time needed in the model for full con-
version of the parent compound. From the results obtained it 
follows that the changes made within the model resulted in a 
somewhat better fit between the predicted and observed data 
with the improvements depending on the assumptions made 
about zonation of the UGTs. In addition it is important to note 
that when extrahepatic metabolism of 1'-OHES would result 
in a substantial formation of 1'-OHES glucuronide the level 
of this urinary metabolite predicted by the zonal models will 
be underestimated. The remaining discrepancy in predicted 
and observed levels of urinary 1'-OHES glucuronide might 
then rather be ascribed to other factors such as formation of 
other—as yet unidentified—metabolites of 1'-OHES reduc-
ing the amount that can be converted to the glucuronide con-
jugate. Additionally it may be due to chemical instability of 
the 1'-OHES (glucuronide) resulting in its isomerisation to 
3'-hydroxyanethole leading to underestimation of the levels of 
1'-OHES (glucuronide) in the urinary samples, or to reduced 
bioavailability of estragole assumed in the present model to be 
100%. In order to understand this discrepancy further studies 
should be performed that were however beyond the scope of 
this study.
Furthermore, it is of interest to note that this study shows 
formation of DNA adducts not only in the liver, but also in 
the kidney and lung of male Sprague Dawley rats treated with 
estragole. These data could however not be compared with pre-
dicted values because the PBBD model did not include equa-
tions to predict DNA adduct formation in extrahepatic tissues. 
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The lower amount of DNA adducts detected in these organs 
reflects the low metabolic conversion of estragole to 1'-OHES 
found in these organs by Punt et  al. (16), although the data 
indicate that these organs do contain the relevant cytochromes 
P450 and conjugating enzymes needed for bioactivation of 
estragole to some extent. To the best of our knowledge this is 
the first time DNA adducts were detected in liver, lung and kid-
ney of estragole-treated rats. Interestingly, DNA adducts were 
detected in vivo in all three organs, but the metabolic capac-
ity for DNA adduct formation and repair in lung and kidney 
is probably unevenly distributed over the different cell types 
in these tissues. This hampers their comparison with the data 
obtained for the liver, the target organ for estragole-induced 
tumour formation, where DNA adduct formation may be more 
evenly distributed.
In conclusion this study reveals a dose-dependent increase 
in estragole–guanine DNA adduct formation in the liver 
of rats exposed to estragole, and also corroborates that the 
now optimised PBBD model can provide a tool to examine 
dose-dependent DNA adduct formation in the liver of rats 
exposed to estragole. Extending this rat PBBD model to the 
human situation will provide a way to extrapolate from rats to 
the human situation including extrapolation from the high-dose 
rat experimental dose levels to low dose levels that are more 
realistic for human exposure regimens. This will provide fur-
ther insight in species and dose-dependent differences or simi-
larities in DNA adduct formation in the liver upon exposure to 
estragole.
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